PharmAthene, Inc, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a multi-year contract for up to $83.9 million for advanced development of a third generation recombinant protective antigen (rPA) anthrax vaccine.
The details can be read here.
No comments:
Post a Comment